TLDR:
- San Diego-based biotechnology startup CRISPR QC has secured funding from Xcellerant Ventures in an ongoing Series A funding round.
- The funding will be used to further develop the CRISPR Analytics Platform, which provides comprehensive measurements and analysis of CRISPR activity.
- CRISPR QC’s proprietary CRISPR-Chip technology allows for direct, real-time measurement of CRISPR activity.
- The company plans to open a satellite office in Sedona, Arizona.
San Diego-based biotechnology startup CRISPR QC has announced that it has secured funding from Xcellerant Ventures in an ongoing Series A funding round. The amount of the deal was not disclosed.
The funding will be used to further develop CRISPR QC’s CRISPR Analytics Platform, which provides comprehensive measurements and analysis of CRISPR activity. This platform enables scientists and researchers to optimize gene editing outcomes and ensure the highest levels of quality control.
CRISPR QC’s analytics platform is built on the company’s proprietary CRISPR-Chip technology, which allows for direct, real-time measurement of CRISPR activity. This technology is an essential tool for researchers using CRISPR gene-editing technology, as it can provide valuable insights into the efficiency and accuracy of the editing process.
In addition to the funding, CRISPR QC also plans to open a satellite office in Sedona, Arizona. The expansion is in response to the company’s growth and will allow for greater accessibility to researchers and customers in the region.
This funding round comes after CRISPR QC closed a seed funding round of $1.6 million in January 2023. The company has been steadily growing since then and continues to attract investment to further develop its technology.
Overall, this funding from Xcellerant Ventures will provide CRISPR QC with the resources needed to continue improving its CRISPR Analytics Platform and expand its reach in the biotechnology market. The ability to directly measure and analyze CRISPR activity in real-time is crucial for researchers using this gene-editing technology, and CRISPR QC’s technology offers a valuable solution in ensuring the highest levels of quality control.
